251 Cases of Soft Tick Relapsing Fever Reported in 2012 to 2021
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, July 20, 2023 -- During 2012 to 2021, 251 cases of soft tick relapsing fever (STRF), caused by certain Borrelia spirochetes and transmitted to humans by soft-bodied Ornithodoros ticks, were reported in 11 states, according to research published in the July 21 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Amy M. Beeson, M.D., from the CDC in Atlanta, and colleagues summarized demographic and clinical information for STRF cases reported during 2012 to 2021.
The researchers identified 251 cases in 11 states during the study period, with a median annual case count of 24. During the study period, there was no significant change in the number of cases observed. Overall, 55 percent of the patients with STRF were hospitalized, but there were no fatalities. Since the 1990s, the geographic distribution and seasonal pattern of STRF have remained relatively constant. In areas where STRF is endemic, persons should avoid rodent-infested structures and habitats, such as caves.
"To reduce STRF incidence in the United States, progress in surveillance, prevention, and disease recognition is needed," the authors write. "Residents and visitors to areas where STRF is endemic should be educated about how to prevent soft tick bites (most importantly, avoidance of rodent-infested structures and rodent habitats such as caves) and when to seek medical care."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.